Table I.
Patients’ and disease characteristics of study cohort (n = 112)
| Parameter | Value |
|---|---|
| Age at diagnosis, median (range) [years] | 56 (range: 19–84) |
| Disease stage, n (%): | |
| Chronic phase | 109 (97) |
| Accelerated phase | 3 (3) |
| Blastic phase | 0 |
| Gender, n (%): | |
| Male | 53 (47) |
| Female | 59 (53) |
| Sokal risk group, n (%): | |
| Low | 34 (30) |
| Intermediate | 60 (54) |
| High | 11 (10) |
| Not applicable | 7 (6) |
| Hasford risk group, n (%): | |
| Low | 43 (39) |
| Intermediate | 44 (40) |
| High | 18 (15) |
| Not applicable | 7 (6) |
| Cytogenetics, n (%): | |
| t (9;22) only | 109 (97) |
| Additional abnormalities | 3 (3) |
| Preview treatment to imatinib, n (%): | |
| Interferon | 11 (10) |
| Hydroxyurea > 1 months | 3 (3) |
| Response to imatinib, n (%): | |
| CHR at 3 months | 108 (96) |
| CCyR at 6 months | 63 (56) |
| MMR at 12 months | 61 (54) |
| Current status, n (%): | |
| Alive | 107 (95.5) |
| Dead | 5 (4.5) |